RESUMEN

Schistosomiasis is considered a serious public health problem in 78 countries and territories located in Africa, Asia and America and it is estimated in more than 249 million people infected by any of the species of Schistosoma. The exclusive use of praziquantel (PZQ), effective drug against all species of Schistosoma, has been the basis of the development of a possible resistance against the strains of this parasite. In addition, PZQ is not effective against young forms of worms. Thus, there is a need for the development of new drugs with schistosomicidal activity. The objective of this work was to synthesize and to evaluate the therapeutic potential of new benzodioxole derivatives (3-14) candidates for schistosomicidal drugs. All compounds synthesized showed in vitro schistosomicidal activity. The derivative 12 was considered the best compound, since it took 100% of worms to mortality in the first 72 h of exposure at the concentration of 100 µM and 83.3% at the concentration of 50 µM. Furthermore, male and female adult worms, incubated for 24 h with the compound 12 showed tegument damages characterized by extensive desquamation and edema, tuber destruction, bubble formation and exposure of the muscle layer. This compound has a restricted structure, where the thiazolidinone is attached to the 4-position of the 1,3-benzodioxol ring. The structural conformation of derivative 12 was probably responsible for the promising schistosomicidal activity, where the presence of an electron/conformational restriction of the thiazolidine ring, as well as the action of bromine as a bulk substitute, favored an increase in biological activity. In addition, tegumentary changes caused by derivative 12 may also have been responsible for the death of adult worms of Schistosoma mansoni. Therefore, we verified that the results obtained in this study make benzodioxole derivatives possible candidates for prototypes of new schistosomicidal drugs.

Asunto(s)

Dioxoles/química , Dioxoles/farmacología , Schistosoma mansoni/efectos de los fármacos , Esquistosomicidas/síntesis química , Esquistosomicidas/farmacología , Animales , Supervivencia Celular/efectos de los fármacos , Dioxoles/uso terapéutico , Células HeLa , Humanos , Microscopía Electrónica de Rastreo , Praziquantel/farmacología , Praziquantel/uso terapéutico , Schistosoma mansoni/ultraestructura , Esquistosomiasis/tratamiento farmacológico , Esquistosomiasis/patología , Esquistosomicidas/uso terapéutico

RESUMEN

OBJECTIVE: Verify the role of the kinin B1 receptors (B1R) and the effect of ACE inhibitors (ACEi) on acute gout induced by monosodium urate (MSU) crystals in rodents. METHODS: Painful (overt pain and allodynia) and inflammatory parameters (joint oedema, leukocyte trafficking, interleukin-1ß levels) of acute gout attacks were assessed several hours after an intra-articular injection of MSU (1.25 or 0.5 mg/articulation) into the ankle of rats or mice, respectively. The role of B1R was investigated using pharmacological antagonism or gene deletion. Additionally, B1R immunoreactivity in ankle tissue and sensory neurons, kininase I activity and des-Arg(9)-bradykinin synovial levels were also measured. Similar tools were used to investigate the effects of ACEi on a low dose of MSU (0.0125 mg/articulation)-induced inflammation. RESULTS: Kinin B1R antagonism or gene deletion largely reduced all painful and inflammatory signs of gout. Furthermore, MSU increased B1R expression in articular tissues, the content of the B1 agonist des-Arg(9)-bradykinin and the activity of the B1 agonist-forming enzyme kininase I. A low dose of MSU crystals, which did not induce inflammation in control animals, caused signs of acute gout attacks in ACEi-treated animals that were B1R-dependent. CONCLUSIONS: Kinin B1R contributes to acute gouty attacks, including the ones facilitated by ACEi. Therefore, B1R is a potential therapeutic target for the treatment and prophylaxis of gout, especially in patients taking ACEi.

Asunto(s)

Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Gota/metabolismo , Receptor de Bradiquinina B1/fisiología , Enfermedad Aguda , Animales , Antagonistas del Receptor de Bradiquinina B1/uso terapéutico , Dioxoles/uso terapéutico , Edema/inducido químicamente , Edema/metabolismo , Gota/inducido químicamente , Gota/tratamiento farmacológico , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Dolor/inducido químicamente , Dolor/metabolismo , Ratas Wistar , Sulfonamidas/uso terapéutico , Ácido Úrico

RESUMEN

PURPOSE: To assess the efficiency of pazopanib compared with trabectedin in the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) after chemotherapy failure. METHODS: The progression of STS was modeled using a partitioned survival analysis model. Survival curves for pazopanib and trabectedin were modeled using data from PALETTE phase III clinical trial and based on unadjusted indirect comparison. Effectiveness was measured in quality-adjusted life years (QALY). The Spanish National Health System perspective was considered over a 10-year time horizon, including direct health care costs (, 2014). A discount rate of 3% was applied to both costs and outcomes. The robustness of the results was evaluated using univariate and probabilistic sensitivity analyses (PSA). RESULTS: Pazopanib was associated with better health outcomes than trabectedin (0.705 versus 0.686 QALY). Pazopanib also showed lower direct health care costs (21,861 versus 45,338), mainly due to lower cost of pharmacological treatment (13,762 versus 33,392), administration (57 versus 2,955) and AE management (658 versus 1,695) costs. PSA confirmed that pazopanib was a dominant option in 71% of the simulations performed. CONCLUSIONS: In this analysis, and from a health economics perspective, pazopanib was the option of choice versus trabectedin in the treatment of adult patients with advanced soft-tissue sarcoma after chemotherapy failure.

Asunto(s)

Antineoplásicos/economía , Antineoplásicos/uso terapéutico , Pirimidinas/economía , Pirimidinas/uso terapéutico , Sarcoma/tratamiento farmacológico , Sulfonamidas/economía , Sulfonamidas/uso terapéutico , Ensayos Clínicos Fase III como Asunto , Análisis Costo-Beneficio , Dioxoles/economía , Dioxoles/uso terapéutico , Progresión de la Enfermedad , Costos de los Medicamentos , Humanos , Indazoles , Probabilidad , Años de Vida Ajustados por Calidad de Vida , Sarcoma/economía , España , Tetrahidroisoquinolinas/economía , Tetrahidroisoquinolinas/uso terapéutico , Trabectedina , Resultado del Tratamiento

RESUMEN

CONTEXT: Fitzroya cupressoides (Molina) I. M. Johnst. and Austrocedrus chilensis (D. Don) Pic.Serm. & Bizzarri are two Chilean Cupressaceae that are naturally resistant to biodegradation. Secondary metabolites from these species display a variety of biological activities. OBJECTIVE: To evaluate the antiproliferative activity of two lignans, a diterpene and a flavonol isolated from A. chilensis and F. cupressoides, to elucidate their cytological effects on P3X murine myeloma cells. MATERIALS AND METHODS: The antiproliferative activity of yatein, isotaxiresinol, ferruginol, and isorhamnetin was evaluated in vitro using the MTT assay. The effect of yatein at the cellular level, due to its high antiproliferative activity was evaluated. P3X cells treated for 24 h with 12.5 and 25 µg/mL of yatein were also examined at the cytological level using immunofluorescence and scanning and transmission electron microscopy. RESULTS: Yatein, a lignan isolated from A. chilensis, potentially inhibited P3X murine myeloma cell proliferation, resulting in approximately 75% cell death in response to a 25 µg/mL treatment with the lignan. P3X cells lost membrane integrity at the nuclear and cytoplasmic levels, including organelles, in response to yatein treatment (12.5 µg/mL), and we observed changes in the cytoplasmic organization and distribution of microtubules. The other compounds tested had low activity. DISCUSSION AND CONCLUSIONS: Yatein is a lignan precursor of podophyllotoxin, a key agent in anticancer drugs. Due to its structural similarities to podophyllotoxin, yatein could have similar cytoplasmic target(s), such as the microtubular apparatus. These findings suggest that yatein may be of potential pharmacological interest and warrants further investigation in human cell lines.

Asunto(s)

4-Butirolactona/análogos & derivados , Antineoplásicos/farmacología , Proliferación Celular/efectos de los fármacos , Cupressaceae , Dioxoles/farmacología , 4-Butirolactona/aislamiento & purificación , 4-Butirolactona/farmacología , 4-Butirolactona/uso terapéutico , Animales , Antineoplásicos/aislamiento & purificación , Antineoplásicos/uso terapéutico , Línea Celular Tumoral , Proliferación Celular/fisiología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Dioxoles/aislamiento & purificación , Dioxoles/uso terapéutico , Ratones , Ratones Endogámicos BALB C

RESUMEN

Multiple sclerosis is an inflammatory disease of the central nervous system. Chronic pain is one of the main symptoms, affecting many patients. Studies show that the lignans or the apolar extracts of Phyllanthus amarus have antinociceptive effects in different animal models. To evaluate the antihypernociceptive effect of a hexanic extract of P. amarus in experimental autoimmune encephalomyelitis in mice, the chemical composition of the hexanic extract was analyzed by gas chromatography mass spectrometry. After EAE induction, animals were treated with the hexanic extract of P. amarus for 26 consecutive days. Motor coordination and mechanical hypernociception were evaluated on alternate days. The principal lignans found were phyllanthin, niranthin, and 5-demethoxyniranthin. The hexanic extract of P. amarus at a dose of 100, 200, or 400 mg/kg did not affect the development of the disease. The motor coordination and pain threshold of the treated animals were not altered in this experiment. In conclusion, in this test, the hexanic extract of P. amarus did not show evidence of antihypernociceptive activity in experimental autoimmune encephalomyelitis.

Asunto(s)

Anisoles/farmacología , Dioxoles/farmacología , Encefalomielitis Autoinmune Experimental , Hiperalgesia , Lignanos/farmacología , Esclerosis Múltiple/complicaciones , Phyllanthus/química , Extractos Vegetales/farmacología , Animales , Anisoles/análisis , Anisoles/uso terapéutico , Dioxoles/análisis , Dioxoles/uso terapéutico , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Femenino , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/etiología , Lignanos/análisis , Lignanos/uso terapéutico , Ratones , Ratones Endogámicos C57BL , Esclerosis Múltiple/tratamiento farmacológico , Extractos Vegetales/química , Extractos Vegetales/uso terapéutico

RESUMEN

Peperomia pellucida is a plant used in traditional medicine to treat gastric ulcers. Although this gastroprotective activity was reported, the active compounds have not been identified. Therefore, the aim herein was to identify the most active compound in the gastroprotective activity of P. pellucida using an ethanol-induced gastric ulcer experimental rat model. A gastroprotective effect was observed when the hexane and dichloromethane extracts were tested, with the higher effect being obtained with the dichloromethane extract (82.3 ± 5.6%) at 100 mg/kg. Dillapiole was identified as the most active compound in this extract. Although there have been previous reports on dillapiole, this is the first on its gastroprotective activity. Rats treated with this compound at 3, 10, 30 and 100 mg/kg showed 23.1, 56.1, 73.2 and 85.5% gastroprotection, respectively. The effect elicited by dillapiole at 100 mg/kg was not attenuated by pretreatment with indomethacin (10 mg/kg, s.c.), a prostaglandin synthesis blocker, NG-nitro-l-arginine methyl ester (70 mg/kg, i.p.), a nitric oxide (NO) synthase inhibitor, or N-ethylmaleimide (10 mg/kg, s.c.), a blocker of sulfhydryl groups. This suggests that the gastroprotective mechanism of action of dillapiole does not involve prostaglandins, NO or sulfhydryl groups.

Asunto(s)

Compuestos Alílicos/farmacología , Dioxoles/farmacología , Peperomia/química , Extractos Vegetales/farmacología , Úlcera Gástrica/tratamiento farmacológico , Compuestos Alílicos/aislamiento & purificación , Compuestos Alílicos/uso terapéutico , Animales , Dioxoles/aislamiento & purificación , Dioxoles/uso terapéutico , Evaluación Preclínica de Medicamentos , Etanol , Masculino , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/uso terapéutico , Ratas , Ratas Wistar , Úlcera Gástrica/inducido químicamente

RESUMEN

Even though the Chagas' disease, caused by the protozoan Trypanosoma cruzi, was described 100years ago by Carlos Chagas, it still represents a major public health concern and is found in 18 developing countries in South and Central America. In Brazil, Benznidazole (Rochagan) is the only drug with trypanocidal activity available in the market, despite its several side effects and limited efficacy in the chronic phase of the infection. In view of the need for new substances displaying biological activity against T. cruzi, there has been growing interest in research toward the attainment of compounds capable of acting on the parasite while being devoid of serious side effects. In this context, this study aims to evaluate the in vivo therapeutic activity of dibenzylbutyrolactone lignans (-)-cubebin and (-)-hinokinin during the acute phase of infection by T. cruzi. As a study criterion, animals with acute parasitemia were investigated by tissue morphometric analysis. There was significant parasitemia reduction in the groups of animals treated with (-)-cubebin or (-)-hinokin oral administration, compared to the negative control. Values close to those of the uninfected control were found in the groups treated with (-)-cubebin and (-)-hinokinin via kariometry, showing that there was positive cellular response compared to the infected control.

Asunto(s)

4-Butirolactona/análogos & derivados , Enfermedad de Chagas/tratamiento farmacológico , Dioxoles/uso terapéutico , Lignanos/uso terapéutico , Tripanocidas/farmacología , Tripanocidas/uso terapéutico , Trypanosoma cruzi/efectos de los fármacos , 4-Butirolactona/química , 4-Butirolactona/farmacología , 4-Butirolactona/uso terapéutico , Animales , Benzodioxoles , Dioxoles/química , Dioxoles/farmacología , Lignanos/química , Lignanos/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Nitroimidazoles/farmacología , Nitroimidazoles/uso terapéutico , Piper/química , Tripanocidas/química

RESUMEN

The ethanol extract from the dried exudate of Bursera fagaroides (Burseraceae) showed significant cytotoxic activity in the HT-29 (human colon adenocarcinoma) test system. The extract provided four podophyllotoxin related lignans, identified as (7'R,8R,8'R)-(-)-deoxypodophyllotoxin (3), (7'R,8R,8'R)-(-)-morelensin (4), (8R,8'R)-(-)-yatein (5), and (8R,8'R)-(-)-5'-desmethoxyyatein (6), whose spectroscopic and chiroptical properties were compared with those of (7R,7'R,8R,8'R)-(-)-podophyllotoxin (1) and its acetyl derivative (2). Their absolute configurations were assigned by comparison of the vibrational circular dichroism spectra of 1 and 3 with those obtained by density functional theory calculations.

Asunto(s)

Adenocarcinoma/tratamiento farmacológico , Antineoplásicos Fitogénicos/química , Bursera/química , Neoplasias del Colon/tratamiento farmacológico , Fitoterapia , Exudados de Plantas/química , Podofilotoxina/análogos & derivados , 4-Butirolactona/análogos & derivados , 4-Butirolactona/química , 4-Butirolactona/farmacología , 4-Butirolactona/uso terapéutico , Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Benzofuranos/química , Benzofuranos/farmacología , Benzofuranos/uso terapéutico , Línea Celular Tumoral , Dicroismo Circular , Dioxoles/química , Dioxoles/farmacología , Dioxoles/uso terapéutico , Medicamentos Herbarios Chinos , Humanos , Espectroscopía de Resonancia Magnética , Estructura Molecular , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Exudados de Plantas/farmacología , Exudados de Plantas/uso terapéutico , Podofilotoxina/química , Podofilotoxina/farmacología , Podofilotoxina/uso terapéutico

RESUMEN

This work aimed to evaluate the effect of diphenyl dimethyl bicarboxylate (DDB) and dexamethasone alone and in combination with praziquantel on various parasitological, immunological and pathological parameters reflecting disease severity and morbidity in murine schistosomiasis. DDB and dexamethasone had no effect on worm burden but altered tissue egg distribution. This indicates that, under the schedule used, neither drug interfered with the development of adult worms or oviposition, but both can modulate liver pathology. Dexamethasone resulted in a greater reduction in granuloma size than did DDB. Dexamethasone-treated mice also showed lower levels of serum gamma interferon (IFN-γ), interleukin-12 (IL-12) and IL-4, together with higher IL-10 levels, than infected untreated control animals. These data suggest that dexamethasone is a convenient and promising coadjuvant agent that results in decreased morbidity in murine schistosomiasis.

Asunto(s)

Adyuvantes Inmunológicos/uso terapéutico , Antihelmínticos/uso terapéutico , Dexametasona/uso terapéutico , Dioxoles/uso terapéutico , Glucocorticoides/uso terapéutico , Praziquantel/uso terapéutico , Esquistosomiasis mansoni/tratamiento farmacológico , Adyuvantes Inmunológicos/administración & dosificación , Animales , Antihelmínticos/administración & dosificación , Citocinas/sangre , Citocinas/inmunología , Dexametasona/administración & dosificación , Dioxoles/administración & dosificación , Quimioterapia Combinada/métodos , Glucocorticoides/administración & dosificación , Granuloma/parasitología , Granuloma/patología , Hígado/parasitología , Hígado/patología , Masculino , Ratones , Praziquantel/administración & dosificación , Esquistosomiasis mansoni/inmunología , Esquistosomiasis mansoni/parasitología , Esquistosomiasis mansoni/patología , Índice de Severidad de la Enfermedad

RESUMEN

The reduction of parasitism tissue upon treatment with two lignano lactones, namely (-)- cubebin (CUB) and (-)-hinokinin (HNK), was evaluated in the chronic phase of Chagas' disease by quantifying the enzyme beta-galactosidase expressed by the CL B5 clone strain of Trypanosoma cruzi. Tissue karyometry was also performed. Treatment with the assessed lignans led to a larger reduction in parasitism tissue in all evaluated organs, compared with benznidazole (BZN). Oral treatment with CUB or HNK was more effective. Karyometry results demonstrated that the infected control animals had increased nuclear area compared with uninfected controls, indicating cellular hypertrophy. Results also revealed that use of CUB or HNK was able to significantly prevent this increase, and a slight decrease in the nuclear area was observed, compared with mice treated with BZN. Taken together, these data demonstrate that CUB and HNK could be considered as potential compounds for the development of new drugs for treatment of Chagas' disease.

Asunto(s)

4-Butirolactona/análogos & derivados , Enfermedad de Chagas/tratamiento farmacológico , Dioxoles/uso terapéutico , Lignanos/uso terapéutico , Tripanocidas/uso terapéutico , Trypanosoma cruzi/efectos de los fármacos , 4-Butirolactona/química , 4-Butirolactona/farmacología , 4-Butirolactona/uso terapéutico , Animales , Benzodioxoles , Enfermedad de Chagas/parasitología , Enfermedad Crónica , Dioxoles/química , Dioxoles/farmacología , Corazón/efectos de los fármacos , Corazón/parasitología , Cariometría , Lactonas/química , Lactonas/farmacología , Lactonas/uso terapéutico , Lignanos/química , Lignanos/farmacología , Hígado/efectos de los fármacos , Hígado/parasitología , Ratones , Ratones Endogámicos BALB C , Bazo/efectos de los fármacos , Bazo/parasitología , Resultado del Tratamiento , Tripanocidas/química , Tripanocidas/farmacología , Trypanosoma cruzi/enzimología , Trypanosoma cruzi/aislamiento & purificación , beta-Galactosidasa/metabolismo

RESUMEN

The (-)-hinokinin display high activity against Trypanosoma cruzi in vitro and in vivo. (-)-Hinokinin-loaded poly(D,L-lactide-co-glycolide) microparticles were prepared and characterized in order to protect (-)-hinokinin of biological interactions and promote its sustained release for treatment of Chagas disease. The microparticles contain (-)-hinokinin were prepared by the classical method of the emulsion/solvent evaporation. The scanning electron microscopy, light-scattering analyzer were used to study the morphology and particle size, respectively. The encapsulation efficiency was determined, drug release studies were kinetically evaluated, and the trypanocidal effect was evaluated in vivo. (-)-Hinokinin-loaded microparticles obtained showed a mean diameter of 0.862 microm with smooth surface and spherical shape. The encapsulation efficiency was 72.46 +/- 2.92% and developed system maintained drug release with Higuchi kinetics. The preparation method showed to be suitable, since the morphological characteristics, encapsulation efficiency, and in vitro release profile were satisfactory. In vivo assays showed significant reduction of mice parasitaemia after administration of (-)-hinokinin-loaded microparticles. Thus, the developed microparticles seem to be a promising system for sustained release of (-)-hinokinin for treatment of Chagas disease.

Asunto(s)

4-Butirolactona/análogos & derivados , Antiprotozoarios/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Preparaciones de Acción Retardada/uso terapéutico , Dioxoles/uso terapéutico , Ácido Láctico/uso terapéutico , Lignanos/uso terapéutico , Microesferas , Ácido Poliglicólico/uso terapéutico , 4-Butirolactona/farmacocinética , 4-Butirolactona/uso terapéutico , Animales , Benzodioxoles , Preparaciones de Acción Retardada/farmacocinética , Dioxanos , Dioxoles/farmacocinética , Modelos Animales de Enfermedad , Humanos , Ácido Láctico/farmacocinética , Lignanos/farmacocinética , Ratones , Parasitemia/tratamiento farmacológico , Ácido Poliglicólico/farmacocinética , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Resultado del Tratamiento , Trypanosoma cruzi/efectos de los fármacos

RESUMEN

Gap junction connexin-43 (Cx43) molecules are responsible for electrical impulse conduction in the heart and are affected by transforming growth factor-â (TGF-â). This cytokine increases during Trypanosoma cruzi infection, modulating fibrosis and the parasite cell cycle. We studied Cx43 expression in cardiomyocytes exposed or not to TGF-â T. cruzi, or SB-431542, an inhibitor of TGF-â receptor type I (ALK-5). Cx43 expression was also examined in hearts with dilated cardiopathy from chronic Chagas disease patients, in which TGF-â signalling had been shown previously to be highly activated. We demonstrated that TGF-â treatment induced disorganised gap junctions in non-infected cardiomyocytes, leading to a punctate, diffuse and non-uniform Cx43 staining. A similar pattern was detected in T. cruzi-infected cardiomyocytes concomitant with high TGF-â secretion. Both results were reversed if the cells were incubated with SB-431542. Similar tests were performed using human chronic chagasic patients and we confirmed a down-regulation of Cx43 expression, an altered distribution of plaques in the heart and a significant reduction in the number and length of Cx43 plaques, which correlated negatively with cardiomegaly. We conclude that elevated TGF-â levels during T. cruzi infection promote heart fibrosis and disorganise gap junctions, possibly contributing to abnormal impulse conduction and arrhythmia that characterise severe cardiopathy in Chagas disease.

Asunto(s)

Adulto , Animales , Femenino , Humanos , Masculino , Ratones , Persona de Mediana Edad , Benzamidas/uso terapéutico , Enfermedad de Chagas/metabolismo , /metabolismo , Dioxoles/uso terapéutico , Uniones Comunicantes/metabolismo , Miocitos Cardíacos/química , Receptores de Factores de Crecimiento Transformadores beta/antagonistas & inhibidores , Factor de Crecimiento Transformador beta/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Técnica del Anticuerpo Fluorescente , Uniones Comunicantes/efectos de los fármacos , Inmunohistoquímica , Microscopía Confocal , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/metabolismo

RESUMEN

Chagas' disease induced by Trypanosoma cruzi infection is an important cause of mortality and morbidity affecting the cardiovascular system for which presently available therapies are largely inadequate. We previously reported that transforming growth factor beta (TGF-beta) is implicated in several regulatory aspects of T. cruzi invasion and growth and in host tissue fibrosis. This prompted us to evaluate the therapeutic action of an inhibitor of TGF-beta signaling (SB-431542) administered during the acute phase of experimental Chagas' disease. Male Swiss mice were infected intraperitoneally with 10(4) trypomastigotes of T. cruzi (Y strain) and evaluated clinically for the following 30 days. SB-431542 treatment significantly reduced mortality and decreased parasitemia. Electrocardiography showed that SB-431542 treatment was effective in protecting the cardiac conduction system. By 14 day postinfection, enzymatic biomarkers of tissue damage indicated that muscle injury was decreased by SB-431542 treatment, with significantly lower blood levels of aspartate aminotransferase and creatine kinase. In conclusion, inhibition of TGF-beta signaling in vivo appears to potently decrease T. cruzi infection and to prevent heart damage in a preclinical mouse model. This suggests that this class of molecules may represent a new therapeutic agent for acute and chronic Chagas' disease that warrants further clinical exploration.

Asunto(s)

Benzamidas/uso terapéutico , Cardiomiopatía Chagásica/prevención & control , Enfermedad de Chagas/tratamiento farmacológico , Dioxoles/uso terapéutico , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Receptores de Factores de Crecimiento Transformadores beta/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Animales , Bradicardia/prevención & control , Masculino , Ratones , Miocardio/patología , Parasitemia/tratamiento farmacológico , Proteínas Serina-Treonina Quinasas/fisiología , Receptor Tipo I de Factor de Crecimiento Transformador beta , Receptores de Factores de Crecimiento Transformadores beta/fisiología

RESUMEN

Gap junction connexin-43 (Cx43) molecules are responsible for electrical impulse conduction in the heart and are affected by transforming growth factor-beta (TGF-beta). This cytokine increases during Trypanosoma cruzi infection, modulating fibrosis and the parasite cell cycle. We studied Cx43 expression in cardiomyocytes exposed or not to TGF-beta T. cruzi, or SB-431542, an inhibitor of TGF-beta receptor type I (ALK-5). Cx43 expression was also examined in hearts with dilated cardiopathy from chronic Chagas disease patients, in which TGF-beta signalling had been shown previously to be highly activated. We demonstrated that TGF-beta treatment induced disorganised gap junctions in non-infected cardiomyocytes, leading to a punctate, diffuse and non-uniform Cx43 staining. A similar pattern was detected in T. cruzi-infected cardiomyocytes concomitant with high TGF-beta secretion. Both results were reversed if the cells were incubated with SB-431542. Similar tests were performed using human chronic chagasic patients and we confirmed a down-regulation of Cx43 expression, an altered distribution of plaques in the heart and a significant reduction in the number and length of Cx43 plaques, which correlated negatively with cardiomegaly. We conclude that elevated TGF-beta levels during T. cruzi infection promote heart fibrosis and disorganise gap junctions, possibly contributing to abnormal impulse conduction and arrhythmia that characterise severe cardiopathy in Chagas disease.

Asunto(s)

Benzamidas/uso terapéutico , Enfermedad de Chagas/metabolismo , Conexina 43/metabolismo , Dioxoles/uso terapéutico , Uniones Comunicantes/metabolismo , Miocitos Cardíacos/química , Receptores de Factores de Crecimiento Transformadores beta/antagonistas & inhibidores , Factor de Crecimiento Transformador beta/uso terapéutico , Adulto , Animales , Enfermedad de Chagas/tratamiento farmacológico , Femenino , Técnica del Anticuerpo Fluorescente , Uniones Comunicantes/efectos de los fármacos , Humanos , Inmunohistoquímica , Masculino , Ratones , Microscopía Confocal , Persona de Mediana Edad , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/metabolismo

RESUMEN

Peptide and non-peptide kinin receptor antagonists were evaluated in cutaneous inflammation models in mice. Topical and i.p. application of kinin B(1) and B(2) receptor antagonists caused a significant inhibition of the capsaicin-induced cutaneous neurogenic inflammatory response. The calculated mean ID(50) for Hoe140 and SSR240612 were 23.83 (9.14-62.14) nmol/kg and 0.23 (0.15-0.36) mg/ear, respectively. The I(max) observed for Hoe140, SSR240612, R-715, FR173657, and FR plus SSR were 61+/-5%, 56+/-3%, 65+/-10%, 48+/-8%, and 52+/-4%, respectively. Supporting these results, double B(1) and B(2) kinin receptors knockout mice showed a significant inhibition of capsaicin-induced ear oedema (42+/-7%). However, mice with a single deletion of either B(1) or B(2) receptors exhibited no change in their capsaicin responses. In contrast, all of the examined kinin receptor antagonists were unable to inhibit the oedema induced by TPA and the results from knockout mice confirmed the lack of kinin receptor signaling in this model. These findings show that kinin receptors are present in the skin and that both kinin receptors seem to be important in the neurogenic inflammatory response. Moreover, non-peptide antagonists were very effective in reducing skin inflammation when topically applied, thereby suggesting that they could be useful tools in the treatment of some skin inflammatory diseases.

Asunto(s)

Antagonistas del Receptor de Bradiquinina B1 , Antagonistas del Receptor de Bradiquinina B2 , Dermatitis/tratamiento farmacológico , Dioxoles/uso terapéutico , Quinolinas/uso terapéutico , Sulfonamidas/uso terapéutico , Animales , Capsaicina/administración & dosificación , Dioxoles/administración & dosificación , Femenino , Masculino , Ratones , Ratones Noqueados , Quinolinas/administración & dosificación , Receptor de Bradiquinina B1/genética , Receptor de Bradiquinina B1/metabolismo , Receptor de Bradiquinina B2/genética , Receptor de Bradiquinina B2/metabolismo , Sulfonamidas/administración & dosificación

RESUMEN

Kinin B1 and B2 receptors are central to the aetiology of pain and inflammation. Constitutive B2 receptors are commonly associated with the acute phase of inflammation and nociception, whereas the inducible B1 receptors are mostly linked to the chronic or persistent phase (or both). Therefore, selective, orally active kinin B1 receptor antagonists could be potentially therapeutic. B1 receptor antagonists have long been exclusively peptides, but recently a few non-peptide representatives have been identified. The clinical potential of these non-peptide molecules has not yet been evaluated, but they might have a role in treating persistent inflammation and pain, especially when no satisfactory therapy is available. This review summarizes recent advances in the identification and the potential therapeutic properties of these molecules.

Asunto(s)

Antagonistas del Receptor de Bradiquinina B1 , Inflamación/tratamiento farmacológico , Dolor/tratamiento farmacológico , Animales , Dioxoles/farmacología , Dioxoles/uso terapéutico , Humanos , Biología Molecular , Relación Estructura-Actividad , Sulfonamidas/farmacología , Sulfonamidas/uso terapéutico

RESUMEN

Previous studies have shown that the extracts obtained from Phyllanthus amarus, and some of the lignans isolated from it, exhibit pronounced antiinflammatory properties. In the present study, we have assessed whether the antiinflammatory actions of these lignans can be mediated by interaction with platelet activating factor (PAF) receptor or interference with the action of this lipid. The local administration of nirtetralin, phyltetralin or niranthin (30 nmol/paw), similar to WEB2170 (a PAF receptor antagonist, 30 nmol/paw), significantly inhibited PAF-induced paw oedema formation in mice. The extracts of P. amarus (100 microg/ml) and niranthin (30 microM), but not nirtetralin or phyltetralin (30 microM), decreased the specific binding of [(3)H]-PAF in mouse cerebral cortex membranes. Furthermore, both niranthin and WEB2170 displaced, in a concentration-dependent manner, the [(3)H]-PAF binding sites. The mean IC(50) values from these effects were 6.5 microM and 0.3 microM, respectively. Additionally, both niranthin and WEB2170 (30 nmol/paw) inhibited the increase of myeloperoxidase activity induced by PAF injection in the mouse paw. When assessed the mouse model of pleurisy induced by PAF, pretreatment with niranthin (100 micromol/kg, p.o.) or WEB2170 (1.7 micromol/kg, i.p.) significantly inhibited PAF-induced protein extravasations. Moreover, in the rat model of PAF-induced allodynia, both niranthin (30 nmol/paw) and WEB2170 (30 nmol/paw) treatment significantly inhibited PAF-induced allodynia. In addition, niranthin had a rapid onset and long-lasting antiallodynic action when compared with WEB2170. Collectively, the present findings suggest that niranthin exhibits antiinflammatory and antiallodynic actions which are probably mediated through its direct antagonistic action on the PAF receptor binding sites.

Asunto(s)

Analgésicos/farmacología , Anisoles/farmacología , Antiinflamatorios/farmacología , Dioxoles/farmacología , Lignanos/farmacología , Phyllanthus , Glicoproteínas de Membrana Plaquetaria/efectos de los fármacos , Receptores Acoplados a Proteínas G/efectos de los fármacos , Analgésicos/metabolismo , Analgésicos/uso terapéutico , Animales , Anisoles/metabolismo , Anisoles/uso terapéutico , Antiinflamatorios/metabolismo , Antiinflamatorios/uso terapéutico , Azepinas/farmacología , Unión Competitiva , Carragenina , Corteza Cerebral/metabolismo , Dioxoles/metabolismo , Dioxoles/uso terapéutico , Inflamación/inducido químicamente , Inflamación/metabolismo , Inflamación/prevención & control , Lignanos/metabolismo , Lignanos/uso terapéutico , Masculino , Ratones , Dimensión del Dolor , Umbral del Dolor/efectos de los fármacos , Peroxidasa/antagonistas & inhibidores , Extractos Vegetales/farmacología , Factor de Activación Plaquetaria/metabolismo , Inhibidores de Agregación Plaquetaria/farmacología , Glicoproteínas de Membrana Plaquetaria/metabolismo , Pleuresia/inducido químicamente , Pleuresia/prevención & control , Ratas , Ratas Wistar , Receptores Acoplados a Proteínas G/metabolismo , Tetrahidronaftalenos/farmacología , Factores de Tiempo , Triazoles/farmacología

RESUMEN

Two novel selective non-peptide kinin B(1) receptor antagonists, the benzodiazepine antagonist and SSR240612, were evaluated in carrageenan-induced mouse pleurisy. The peptide R-715 (0.5 mg/kg, i.p.) and the non-peptide benzodiazepine (3 mg/kg, i.p.) antagonists significantly decreased cellular migration (predominantly neutrophils), without altering plasma exudation. SSR240612 (1 mg/kg, i.p.) diminished total cells and neutrophils, besides exudation. Oral administration of SSR240612 (10 mg/kg) also reduced total cell and neutrophil counts. Only the benzodiazepine antagonist inhibited the lung myeloperoxidase activity. No tested antagonist significantly altered the lung and pleural TNFalpha and IL-1beta production. We provide interesting evidence on the anti-inflammatory in vivo effects of non-peptide B(1) receptor antagonists.

Asunto(s)

Antagonistas del Receptor de Bradiquinina B1 , Bradiquinina/análogos & derivados , Carragenina , Dioxoles/uso terapéutico , Pleuresia/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Animales , Benzodiazepinas/antagonistas & inhibidores , Bradiquinina/uso terapéutico , Modelos Animales de Enfermedad , Femenino , Interleucina-1beta/efectos de los fármacos , Pulmón/metabolismo , Masculino , Ratones , Estructura Molecular , Peroxidasa/efectos de los fármacos , Peroxidasa/metabolismo , Pleuresia/inducido químicamente , Factor de Necrosis Tumoral alfa/efectos de los fármacos